Get the Stockscreener App
23.70
0.34%
0.08
Pre-market:
23.12
-0.58
-2.45%
Greenwich Lifesciences Inc stock is traded at $23.70, with a volume of 115.25K.
It is up +0.34% in the last 24 hours and up +3.22% over the past month.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
See More
Previous Close:
$23.62
Open:
$23.46
24h Volume:
115.25K
Relative Volume:
0.67
Market Cap:
$328.35M
Revenue:
-
Net Income/Loss:
$-19.48M
P/E Ratio:
-16.19
EPS:
-1.4641
Net Cash Flow:
$-8.59M
1W Performance:
-2.11%
1M Performance:
+3.22%
6M Performance:
+157.33%
1Y Performance:
+137.47%
1-Day Range:
$22.92
$24.90
1-Week Range:
$21.25
$24.96
52-Week Range:
$7.78
$34.10
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
23.70 | 328.35M | 0 | -19.48M | -8.59M | -1.4641 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | Noble Capital Markets | Outperform |
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
(GLSI) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Greenwich LifeSciences delays annual report filing - Investing.com UK
Greenwich LifeSciences delays annual report filing By Investing.com - Investing.com South Africa
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing - The Manila Times
Europe trial enrollment jump leaves Greenwich finalizing 10-K figures - Stock Titan
GLSI Stock Price, Quote & Chart | GREENWICH LIFESCIENCES INC (NASDAQ:GLSI) - ChartMill
Why did Greenwich LifeSciences stock soar pre-market today? - MSN
Why is GLSI stock rising today? - MSN
Greenwich LifeSciences receives Nasdaq notice regarding late Form 10-K filing - MSN
Greenwich LifeSciences (NASDAQ:GLSI) Cut to "Sell" at Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Greenwich LifeSciences (GLSI) and Actinogen Medical (OtherATGGF) - The Globe and Mail
GLSI Technical Analysis | Trend, Signals & Chart Patterns | GREENWICH LIFESCIENCES INC (NASDAQ:GLSI) - ChartMill
HC Wainwright Has Bearish Estimate for GLSI FY2026 Earnings - MarketBeat
ASCO 2026 to feature Greenwich LifeSciences research poster - Traders Union
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026 - ChartMill
GLSI (Greenwich LifeSciences Inc.) reports narrow Q3 2025 EPS beat, shares climb 2.36 percent on positive investor sentiment.Hedge Fund Inspired Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing - ChartMill
H.C. Wainwright Maintains Greenwich LifeSciences(GLSI.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Nasdaq flags Greenwich LifeSciences over delayed 2025 annual report - Stock Titan
(GLSI) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Why Did GLSI Stock Rise Pre-Market Today? - Stocktwits
Greenwich LifeSciences shares rise on breast cancer vaccine trial data By Investing.com - Investing.com Canada
Greenwich LifeSciences unveils preliminary FLAMINGO-01 open label data at AACR Meeting - Traders Union
Breast cancer immunotherapy shows 4x immune response in Phase III data - Stock Titan
Is Greenwich LifeSciences (GLSI) stock still attractive (Bullish Sentiment) 2026-04-18Stock Idea Sharing Hub - Xã Thanh Hà
Greenwich LifeSciences (GLSI) Stock Rule Based Trade (Investors Pile In) 2026-04-16Shared Buy Zones - Xã Châu Thành
Greenwich LifeSciences (GLSI) Stock Rights Issue (At Lows) 2026-04-15Viral Trades - Cổng thông tin điện tử tỉnh Lào Cai
Greenwich Lifesciences Provides Clinical Trial and Pipeline Update - National Today
Greenwich LifeSciences reports Q1 cash balance of $10.5 million By Investing.com - Investing.com Australia
Strategic financing update revealed by Greenwich LifeSciences - Traders Union
Greenwich LifeSciences, Inc. Provides Financial Updates and Progress on FLAMINGO-01 Phase III Trial for Breast Cancer Immunotherapy GLSI-100 - Quiver Quantitative
Greenwich LifeSciences reports Q1 cash balance of $10.5 million - Investing.com
Greenwich LifeSciences Provides Update on Financing Strategy - ChartMill
Greenwich LifeSciences (GLSI) Expected to Announce Earnings on Tuesday - MarketBeat
Portfolio Shifts: Can Greenwich LifeSciences Inc expand into new markets2026 Recap & Detailed Earnings Play Strategies - baoquankhu1.vn
Greenwich Lifesciences Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Aug Retail: Will Greenwich LifeSciences Inc benefit from current market trendsTrade Risk Assessment & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Will Greenwich LifeSciences Inc benefit from current market trends2026 Market Outlook & Weekly Hot Stock Watchlists - baoquankhu1.vn
(GLSI) Risk Channels and Responsive Allocation - Stock Traders Daily
Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01 - ADVFN
Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential - Sahm
Greenwich LifeSciences: 'Buy' On Recent Open-Label Data And Patent Claim - Seeking Alpha
Greenwich LifeSciences files patent claims for breast cancer therapy By Investing.com - Investing.com South Africa
Greenwich LifeSciences advances new patent claims after FLAMINGO-01 data show statistically significant immune response - Traders Union
Greenwich LifeSciences files patent claims for breast cancer therapy - Investing.com
Greenwich Lifesciences Provides Update On Patent Claims Potentially Doubling Gp2 Market Potential - TradingView
Valuation Update: Can Greenwich LifeSciences Inc expand into new marketsMarket Sentiment Report & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):